N/A
Completed N=42
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
Psoriasis Chronic
Source: ClinicalTrials.gov NCT01084668 ↗
Enrolled (actual)
42
Serious AEs
2.4%
Results posted
May 2012
Primary outcomePrimary: Psoriasis Area and Severity Index (PASI) Score — 15.5; 7.6; 2.5; 2.0 units on a scale
Summary
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe chronic plaque psoriasis after unsustainable clinical response to other biologic disease modifying anti-rheumatic drugs (BDMARDs). There are few data so far showing the effects of switching from other BDMARDs to adalimumab in patients with moderate to severe chronic plaque psoriasis. This study was designed to evaluate the long-term effectiveness of adalimumab in participants with moderate to severe chronic plaque psoriasis using the Psoriasis Area and Severity Index (PASI) in participants previously treated with efalizumab, infliximab, or etanercept and who either never achieved satisfactory response, achieved satisfactory response initially but lost it over time, or discontinued treatment due to intolerance/side effect(s) or other reasons, for example after regular stop of etanercept.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Psoriasis Area and Severity Index (PASI) Score |
15.5; 7.6; 2.5; 2.0 | — |
| PRIMARY Reduction in Psoriasis Area and Severity Index Score of at Least 75% (PASI75) |
23 | — |
| SECONDARY Dermatology Life Quality Index (DLQI) Score |
13.8; 7.2; 2.2; 2.2 | — |
| SECONDARY Nail Psoriasis Severity Index (NAPSI) Score |
15.4; 29.0; 14.9; 28.0; 4.0; 7.9 | — |
| SECONDARY Tolerability and Safety Assessed by Collection and Classification of Adverse Reactions |
8; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients for whom adalimumab therapy is indicated and has been prescribed according to the product label
- Patients aged 18 years and older
- Unsatisfactory response to prior BDMARDS (efalizumab, infliximab, etanercept) in patients with moderate to severe chronic plaque psoriasis or achievement of satisfactory response initially, but loss over time or discontinuation of treatment due to intolerance/side effects(s) or other reasons e.g. restart after regular stop of etanercept
- Patients must fulfill Austrian Treatment Recommendations for use of BDMARD in psoriasis (chest X-ray and purified protein derivative [PPD] skin test negative for tuberculosis)
- Patient is willing to consent to data being collected and provided to Abbott
- Patient must be able and willing to self-administer Pen injections or have a qualified person available to administer Pen injections
Exclusion Criteria
- Patients who meet contraindications as outlined in the latest version of the Humira-Pen Summary of Product Characteristics (SPC)
- Patients who do not meet the criteria for the use of BDMARDs of the Austrian Treatment Recommendations
- Patients participating in another study or clinical trial
Data sourced from ClinicalTrials.gov (NCT01084668). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.